The University of Texas System

Pharmacyclics, Inc.

Other

The University of Arizona

H. Lee Moffitt Cancer Center and Research Institute, Inc.

Intezyne Technologies, Incorporated

Korea University Research and Business Foundation

Wright State University

Galileo Pharmaceuticals, Inc.

Baylor Research Foundation

Georgia Southern University

Gyeongsang National University

Gregory W. Hemmi

Jonathan L. Sessler

Toshiaki Murai

Jonathan L Sessler

Gregory W Hemmi

Tarak D Mody

Darren Magda

Brent L Iverson

Vladimir A Kral

Vladimir A Kr Al

Richard A Miller

Anthony M Harriman

Meredith Wright

Hiroyuki Furuta

Petra I Sansom

Kevin Shreder

Kevin N Sill

Victor J Hruby

Robert J Gillies

David L Morse

Josef Vagner

Narges Tafreshi

Christian Preihs

Richard E Thomas

Natalie M Barkey

Jonathan Arambula

Andrei Andrievsky

Zahid H Siddik

Shaun P Crofts

Christopher W Bielawski

Gregory Thiabaud

William E Allen

William C Dow

Takashi Morishima

Greg Hemmi

Bhaskar G Maiya

Michael J Cyr

Steven J Weghorn

Abdullah Aydogan

Daniel J Coady

Daniel A Smith

Andreas Gebauer

Christopher T Brown

Vincent Lynch

Philip A Gale

Bing Wang

Millard M Judy

Norbert Purro

J Lester Matthews

Min Goo Lee

Stuart W Young

Satyanarayana Janagani

Joan F Carvalho

Joseph T Newman

Manuel Marquez

Christopher K Black

Jong Seung Kim

Pavel Anzenbacher, Jr

Petra L Jansen

Kevin L Ross

Sung Kuk Kim

Qing He

Sharon Hannah

Frank Sogandares-Bernal

Kuppuswamy Arumugam

Amit Sharma

Miae Won

Sung-Gil Chi

Patricia J Pantos

Vladimír A Král

James A Shriver

Daniel Seidel

Frederic R Bolze

Thomas Koehler

Wyeth B Callaway

Andrew Carl Try

Bruno Andrioletti

Jin Yong Lee

Vladim&iacute;r A Kr&aacute;l

John W Genge

Murai Toshiaki

The present disclosure relates platinum(IV) and texaphyrin linked conjugates and compositions comprising a texaphyrin and a platinum(IV) agent. The present disclosure also provides pharmaceutical compositions of the conjugates and compositions. Also, provided herein are methods of using the instant compounds in the treatment of cancer such as a platinum resistant cancer.

Texaphyrin-Pt(IV) conjugates and compositions for use in overcoming platinum resistance

The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imagable contrast agent and/or anti-cancer agent) selectively to the tumor cell.

Melanocortin 1 receptor ligands and methods of use

The present disclosure relates to calixpyrrole compounds and compositions thereof. The calixpyrrole compounds are chemical groups which are located in such a manner so as to be useful for the selective extraction of specific salts. Also provided herein are compositions and methods of use thereof.

Compounds for the selective solid-liquid extraction and liquid-liquid extraction of lithium chloride

The present disclosure relates gold carbene naphthoquinone compounds and salts thereof. In some aspects, these compounds can be used to treat cancer including cancers which are resistant to one or more other chemotherapeutic agents such as cisplatin or platinum chemotherapeutic agents. Also provided herein are pharmaceutical compositions comprising the gold carbene naphthoquinone compounds.

Naphthoquinone containing gold carbene complexes and methods of uses thereof

Disclosed is an anticancer prodrug that disturbs energy metabolism in cancer cells to overcome drug resistance. The anticancer prodrug has a structure including a pyruvate dehydrogenase kinase (PDK) inhibitor moiety, a mitochondrial targeting group, and an anthracycline moiety reversibly connected to the PDK inhibitor moiety and the targeting group.

Anticancer prodrug for overcoming drug resistance

The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.

Polymeric compounds containing polymer backbones functionalized with ion-specific recognition elements and methods for the use of these compounds are described herein. The polymeric compounds may contain multiple types of ion-specific recognition elements depending on a specific application. The polymeric compounds can be used to remove ionic species from a solution, for example, in separations applications in which a single or multiple types of ionic species are desired to be removed from the solution.

Polymers functionalized with ion-specific recognition elements

Disclosed are functionalized expanded porphyrins that can be used as spectrometric sensors for high-valent actinide cations. The disclosed functionalized expanded porphyrins have the advantage over unfunctionalized systems in that they can be immobilized via covalent attachment to a solid support comprising an inorganic or organic polymer or other common substrates. Substrates comprising the disclosed functionalized expanded porphyrins are also disclosed. Further, disclosed are methods of making the disclosed compounds (immobilized and free), methods of using them as sensors to detect high valent actinides, devices that comprise the disclosed compounds, and kits.

Functionalized expanded porphyrins

Disclosed herein are novel zinc ionophores, zinc chelators and/or zinc complexes with enhanced aqueous solubility. Methods of treating cancer using at least one zinc ionophore and/or zinc chelator are also disclosed. Also disclosed herein are compositions and methods for treating cancer with combination therapy using at least one texaphyrin metal complex and at least one zinc ionophore or the respective pharmaceutically acceptable derivatives or salts thereof.

Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer

Growing community of inventors

Austin, TX, United States of America

Jonathan L Sessler